PTC Therapeutics, Inc.
100 Corporate Court
South Plainfield
New Jersey
07080-2449
United States
Tel: 908-222-7000
Fax: 908-222-7231
Website: http://www.ptcbio.com/
326 articles with PTC Therapeutics, Inc.
-
PTC Therapeutics Announces Initial Data from Patient Registry Demonstrating Translarna™ (ataluren) Slows Disease Progression in Children with Duchenne Caused by a Nonsense Mutation
10/6/2018
Analysis of data to date shows Translarna Preserved Ambulation for up to 5 Years Compared to Natural History
-
Risdiplam Demonstrates Preliminary Evidence of Clinical Benefit in Type 1, 2, & 3 Spinal Muscular Atrophy Patients
10/3/2018
Babies from FIREFISH Part 1 study showed increased survival & gains in developmental milestones
-
PTC Therapeutics announced interim data from Part 1 of its open-label clinical trials, FIREFISH and SUNFISH, of risdiplam for Type 1, 2 and 3 spinal muscular atrophy in collaboration with Genentech.
-
VelosBio raised $58 million in a Series A financing. It was co-led by Arix Bioscience, which committed $11 million, which will give them an 11.2 percent ownership stake, and Sofinnova Ventures.
-
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) on September 25, 2018
9/28/2018
PTC Therapeutics, Inc. today announced that on September 25, 2018 it approved non-statutory stock options to purchase an aggregate of 122,200 shares of its common stock to 33 new employees.
-
PTC Therapeutics to Participate at Upcoming October 2018 Investor Conference
9/25/2018
PTC Therapeutics, Inc. today announced that management will present a company update at Chardan Genetic Medicines Conference on Tuesday, October 9th at 2:00 p.m. EST.
-
BioSpace Movers and Shakers Sept. 24
9/24/2018
Here's a look at who's making moves in the biotech and pharma world this week. -
PTC Therapeutics to Participate at Upcoming Investor Conference on September 27 2018
9/13/2018
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at Jefferies Gene Therapy Summit on Thursday, September 27th at 1:30 p.m. EST.
-
Movers and Shakers for Sept. 10
9/10/2018
Let's take a look at who made a splash in the pharma and biotech world the past week. -
This week has several action dates by the U.S. Food and Drug Administration (FDA) for a range of indications, including acne, intra-abdominal infections, and rare liver diseases. Here’s a look.
-
PTC Therapeutics Reports Inducement Grants of 381,500 Shares of its Common Stock Under Nasdaq Listing Rule 5635(c)(4)
8/24/2018
PTC Therapeutics, Inc. today announced that on August 22, 2018 it approved non-statutory stock options to purchase an aggregate of 381,500 shares of its common stock to 15 new employees.
-
PTC Therapeutics Successfully Completes Acquisition of Agilis Biotherapeutics
8/23/2018
With the acquisition, PTC adds GT-AADC, an adeno-associated virus (AAV) gene therapy that treats Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency.
-
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) on August 6, 2018
8/10/2018
PTC Therapeutics, Inc. announced that on August 6, 2018 it approved non-statutory stock options to purchase an aggregate of 170,200 shares of its common stock to 27 new employees.
-
PTC Therapeutics Reports Second Quarter 2018 Financial Results and Provides a Corporate Update
8/7/2018
Entered into agreement to acquire Agilis Biotherapeutics
-
Akcea Therapeutics and PTC Therapeutics Collaborate to Commercialize Two Rare Disease Drugs in Latin America
8/2/2018
PTC in-licenses regional rights to TEGSEDI™ and WAYLIVRA™ from Akcea
-
Dedicated Online Platform DuchenneXchange.org Launches to Unite, Support and Educate Duchenne Community
7/31/2018
The Duchenne muscular dystrophy (DMD) community now has a dedicated online platform where they can connect and share knowledge - DuchenneXchange (DuchenneXchange.org)
-
PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2018 Financial Results
7/26/2018
PTC Therapeutics, Inc. announced that the Company will host a webcast conference call to report its second quarter 2018 financial results and provide an update on the company's business and outlook on Tuesday, August 7, 2018 at 4:30 p.m. (ET) after closing of the market.
-
PTC Therapeutics Announces Publication of Data Demonstrating the Clinical Differentiated Benefit of Deflazacort
7/24/2018
Post hoc analysis of the placebo arm of ACT DMD Data Published in Muscle & Nerve
-
PTC Therapeutics is buying Agilis Biotherapeutics in a deal that has the potential to exceed $945 million.
-
PTC Therapeutics to Acquire Agilis Biotherapeutics
7/19/2018
PTC Therapeutics, Inc., today announced that it has entered into an agreement to acquire Agilis Biotherapeutics, Inc., a biotechnology company advancing an innovative gene therapy platform for rare monogenic diseases that affect the central nervous system (CNS). The transaction was approved by the Boards of both companies.